Compare RELL & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | BDTX |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.3M | 171.9M |
| IPO Year | 2004 | 2020 |
| Metric | RELL | BDTX |
|---|---|---|
| Price | $17.79 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 319.4K | ★ 2.0M |
| Earning Date | 04-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,909,000.00 | N/A |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.79 | $1.93 |
| 52 Week High | $19.86 | $4.94 |
| Indicator | RELL | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.83 | 40.15 |
| Support Level | $10.10 | N/A |
| Resistance Level | $19.86 | $2.30 |
| Average True Range (ATR) | 1.56 | 0.30 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 56.79 | 2.78 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.